Eli Lilly touts PhIII success for Taltz as rival Novartis stays well out front in crowded immunology race
The chess pieces are moving again in the blockbuster marketing game of immunology drugs.
This morning it’s Eli Lilly’s $LLY turn to make a move …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
